Clinical and Laboratory Characteristics Are Associated With Biologic Therapy Use in Pediatric Inflammatory Bowel Disease: A Retrospective Cohort Study.
Biologic therapy
IBD natural history
IBD outcomes
IBD therapy
Journal
Journal of the Canadian Association of Gastroenterology
ISSN: 2515-2092
Titre abrégé: J Can Assoc Gastroenterol
Pays: England
ID NLM: 101738684
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
22
05
2020
accepted:
15
09
2020
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
8
10
2021
Statut:
epublish
Résumé
Biologic agents are a highly useful class of medications for treating inflammatory bowel disease (IBD). Limited evidence exists to guide initiation of biologic therapy, especially in pediatric patients. It is unclear if disease severity is connected to biologic response. We hypothesized that the clinical, biochemical and radiographic characteristics of pediatric IBD at diagnosis were associated with subsequent initiation of biologic therapy. We performed a retrospective analysis of the charts of all pediatric patients diagnosed with IBD at our centre over 14 years. Kaplan-Meier curves evaluated patient characteristics at diagnosis with time to initiation of biologic therapy. A Cox proportional hazards model was used for multivariate characteristic analysis. A total of 198 patients were included, 57.6% had Crohn's disease, 27.8% had ulcerative colitis and 14.6% had IBD type unclassified. Mean follow-up time was 47.8 months. About 55.5% of the patients received a biologic medication, the mean time to biologic initiation was 21.5 months. Earlier initiation of biologic therapy was frequently associated with older age, higher disease activity index and lower serum albumin. Older pediatric patients with more severely active disease and lower serum albumin levels at the time of IBD diagnosis were more likely to initiate biologic therapy when considering biologic initiation, even many years after diagnosis. Identification of these characteristics may help inform decisions to initiate biologic therapy earlier in the IBD disease course.
Sections du résumé
BACKGROUND
BACKGROUND
Biologic agents are a highly useful class of medications for treating inflammatory bowel disease (IBD). Limited evidence exists to guide initiation of biologic therapy, especially in pediatric patients. It is unclear if disease severity is connected to biologic response. We hypothesized that the clinical, biochemical and radiographic characteristics of pediatric IBD at diagnosis were associated with subsequent initiation of biologic therapy.
METHODS
METHODS
We performed a retrospective analysis of the charts of all pediatric patients diagnosed with IBD at our centre over 14 years. Kaplan-Meier curves evaluated patient characteristics at diagnosis with time to initiation of biologic therapy. A Cox proportional hazards model was used for multivariate characteristic analysis.
RESULTS
RESULTS
A total of 198 patients were included, 57.6% had Crohn's disease, 27.8% had ulcerative colitis and 14.6% had IBD type unclassified. Mean follow-up time was 47.8 months. About 55.5% of the patients received a biologic medication, the mean time to biologic initiation was 21.5 months. Earlier initiation of biologic therapy was frequently associated with older age, higher disease activity index and lower serum albumin.
CONCLUSIONS
CONCLUSIONS
Older pediatric patients with more severely active disease and lower serum albumin levels at the time of IBD diagnosis were more likely to initiate biologic therapy when considering biologic initiation, even many years after diagnosis. Identification of these characteristics may help inform decisions to initiate biologic therapy earlier in the IBD disease course.
Identifiants
pubmed: 34617006
doi: 10.1093/jcag/gwaa033
pii: gwaa033
pmc: PMC8489526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e92-e100Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
Références
Gastroenterology. 2014 Feb;146(2):383-91
pubmed: 24162032
Scand J Gastroenterol. 1992 Sep;27(9):774-8
pubmed: 1411285
Inflamm Bowel Dis. 2015 Sep;21(9):2114-22
pubmed: 26218144
Gastroenterol Clin North Am. 2009 Dec;38(4):577-94
pubmed: 19913203
Inflamm Bowel Dis. 2011 Jun;17(6):1314-21
pubmed: 21560194
Lancet. 2017 Apr 29;389(10080):1710-1718
pubmed: 28259484
J Pediatr Gastroenterol Nutr. 1991 May;12(4):439-47
pubmed: 1678008
Gastroenterology. 2007 Aug;133(2):423-32
pubmed: 17681163
N Engl J Med. 2004 Feb 26;350(9):876-85
pubmed: 14985485
J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):140-5
pubmed: 20453677
Gastroenterology. 2015 Oct;149(5):1275-1285.e2
pubmed: 26166315
Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):537-45
pubmed: 26284562
J Crohns Colitis. 2014 Oct;8(10):1179-207
pubmed: 24909831
Inflamm Bowel Dis. 2007 Apr;13(4):424-30
pubmed: 17206672
Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):86-92
pubmed: 20134490
J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):e25-e27
pubmed: 27741061
Scand J Gastroenterol. 2009;44(4):431-40
pubmed: 19101844
J Can Assoc Gastroenterol. 2019 Aug;2(3):e35-e63
pubmed: 31294379
Lancet. 2008 Feb 23;371(9613):660-667
pubmed: 18295023